You are here

What’s the Stem Cells Buzz this Week? - ASC-mediated Vasculogenesis, Inhibition of PSC Tumorigenesis, Stem Cells and Cancer, and MSC Characterization!



The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

ASC-derived NOTCH2 Promotes Vasculogenesis

Researchers from the lab of Vincenzo Terlizzi (University of Groningen, Netherlands) hope that adipose tissue-derived stem cells (ASC) can functionally replace the pericytes lost during diabetic retinopathy (DR) and boost the formation of the vasculature. Their new study demonstrates that NOTCH2 secretion by ASCs promotes in vitro vasculogenesis in 2D and 3D in vitro and promotes ASC migration to the retinal microenvironment. For all the details on this fascinating study, head over to STEM CELLS now.

A New Means to inhibit hPSC Tumorigenesis

While the transplantation of cells derived from human pluripotent stem cells (hPSCs) seems to have a bright future, there still exist concerns regarding the potential tumorigenicity of “leftover” undifferentiated cells. To combat these fears, the group of Ken-ichiro Kosai (Kagoshima University, Japan) has described a novel method for the efficient generation of tumorigenic cell-targeting lentiviral vectors (TC-LVs) with various promoters upstream of a fluorescent protein and suicide genes. See STEM CELLS for all the fine print on this new tumorigenic cell-killing strategy.

MSCs and Cancer: A Review

Studies suggest that mesenchymal stem cells (MSCs) may play roles in both the promotion and inhibition of cancer progression.  A new review article from the lab of Gianpaolo Papaccio (Università degli Studi della Campania, Naples, Italy) discusses recent findings in the hope of clarifying the pivotal role of MSCs in cancer development and determining their potential use in cancer treatment. See STEM CELLS now for a great read!

Characterizing MSCs: An Essential Step for Regenerative Medicine

The widespread application of mesenchymal stem cells (MSCs) in regenerative therapies inspired our next review from the labs of Simon Cool (A-STAR, Singapore) and Andre van Wijnen (Mayo Clinic, USA). The authors suggest that wide-ranging characterization metrics for MSCs may more accurately predict treatment outcomes of MSC-based therapies. Additionally, the duo discuss currently appreciated characteristics of MSCs and consider recent studies that describe potentially valuable criteria when considering clinical applications. STEM CELLS Translational Medicine has all the juicy details, what are you waiting for?!

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!